Post by Biocytogen

🔬 Breaking through the stromal barrier in solid tumors Stroma-rich solid tumors remain one of the biggest challenges for ADC therapy. BCG026, our FAP × GPC-1 bispecific ADC, is designed to overcome poor drug penetration and antigen escape with a dual-targeting strategy. Key advantages: ► Converts FAP⁺ stroma into a drug-delivery hub ► Superior efficacy in preclinical PDX models ► Wider therapeutic window through avidity-driven cooperative internalization ► RenLite® platform-enabled with dual-payload potential 🤝 We're looking for partners to bring BCG026 to the clinic. If you're developing next-generation ADCs for solid tumors, let's start the conversation. 👉 Learn more about this asset: https://lnkd.in/eX_U3nzy #Biocytogen #ADC #BispecificADC #Oncology #PancreaticCancer #DrugDiscovery #CancerResearch